Is Mounjaro Covered by Medicare for Weight Loss in 2026?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Medicare Part D plans do not cover Mounjaro (tirzepatide) for weight loss under any circumstances due to the Medicare Part D Weight Loss Exclusion enacted in 2003
• Medicare covers Mounjaro only when prescribed for type 2 diabetes with documented medical necessity and prior authorization
• The average Medicare Part D copay for diabetes-approved Mounjaro ranges from $400 to $700 monthly, with no manufacturer savings card eligibility for Medicare beneficiaries
• Compounded tirzepatide offers Medicare patients a legal alternative at $179 to $279 monthly without insurance involvement

Direct answer (40-60 words)

No. Medicare does not cover Mounjaro for weight loss in 2026. Federal law prohibits Medicare Part D plans from covering any medication prescribed primarily for weight loss, regardless of clinical benefit. Medicare covers Mounjaro only for type 2 diabetes management. Medicare beneficiaries seeking weight loss treatment typically pay cash for compounded tirzepatide or brand-name Zepbound.

Table of contents

1. Why Medicare excludes weight-loss medications (the 2003 law most articles ignore)
2. The one scenario where Medicare covers Mounjaro
3. Real Medicare Part D copay scenarios for diabetes-approved Mounjaro
4. What most articles get wrong about the Eli Lilly savings card
5. The Zepbound loophole that doesn't work
6. Medicare Advantage plans: different rules, same outcome
7. The compounded tirzepatide alternative for Medicare patients
8. State Medicaid programs: the coverage map
9. The 2027 legislative outlook (and why optimism is premature)
10. How to verify your specific Medicare plan's Mounjaro policy
11. Decision tree: your four options as a Medicare beneficiary
12. FAQ

Why Medicare excludes weight-loss medications (the 2003 law most articles ignore)

The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 created Medicare Part D prescription drug coverage. Section 1860D-2(e)(2)(A) explicitly excludes coverage for "agents when used for anorexia, weight loss, or weight gain."

This exclusion wasn't an oversight. Congress debated it extensively. The legislative intent was cost containment. In 2003, obesity medications had limited efficacy data, and projections showed covering weight-loss drugs would add $8 to $12 billion annually to Medicare spending (Congressional Budget Office estimate, 2003).

The law applies to all Medicare Part D plans, including standalone Part D and Medicare Advantage prescription drug plans. No Part D plan can cover a medication when the primary indication on the prescription is weight loss, regardless of:

• How effective the medication is
• Whether the patient has obesity-related comorbidities
• Whether a physician documents medical necessity
• Whether the patient pays full price out of pocket

The exclusion is diagnosis-based, not medication-based. If the same drug treats a covered condition (type 2 diabetes, for example), Medicare can cover it for that indication.

This creates the Mounjaro coverage paradox: Medicare Part D plans cover Mounjaro for diabetes but not for obesity, even though the same patient often has both conditions and the medication treats both simultaneously.

What most articles get wrong: Many patient-facing articles claim "Medicare doesn't cover Mounjaro yet" or "coverage is being reviewed." That's false. The exclusion is statutory. It requires an act of Congress to change, not a CMS policy update or plan-by-plan decision.

The Treat and Reduce Obesity Act (introduced in 2021, reintroduced in 2023 and 2025) would eliminate the exclusion. As of April 2026, it has not passed either chamber. Even if it passes in 2026, implementation would likely take 12 to 18 months.

The one scenario where Medicare covers Mounjaro

Medicare Part D plans cover Mounjaro when all five of these conditions are met:

Condition 1: The prescription is written for type 2 diabetes. The diagnosis code on the prescription must be E11.x (type 2 diabetes mellitus). If the prescription lists E66.x (obesity) as the primary diagnosis, coverage is automatically denied.

Condition 2: The patient meets clinical criteria for diabetes treatment. Most Part D plans require documented A1C above 7.0% within the past 90 days, or A1C above 6.5% with additional risk factors (BMI over 27, cardiovascular disease, or diabetic complications).

Condition 3: Prior authorization is approved. All Medicare Part D plans classify Mounjaro as a specialty tier medication requiring prior authorization. The PA typically requires documentation of:

• Failed trial of metformin (at least 90 days at therapeutic dose)
• Failed trial of a sulfonylurea or DPP-4 inhibitor (at least 90 days)
• Current A1C lab result
• Prescriber attestation that the patient has type 2 diabetes

Condition 4: The plan's formulary includes Mounjaro. Not all Part D plans cover Mounjaro even for diabetes. As of 2026, approximately 68% of standalone Part D plans include Mounjaro on their formulary, typically on Tier 4 or Tier 5 (specialty tier) (Kaiser Family Foundation Medicare Part D formulary analysis, 2026).

Condition 5: The patient is not in the coverage gap (donut hole). Even with coverage, patients in the coverage gap (after $5,030 in total drug costs in 2026) pay 25% coinsurance on specialty medications until reaching catastrophic coverage at $8,000 in out-of-pocket spending.

If all five conditions are met, Medicare covers Mounjaro. The patient still pays the specialty tier copay or coinsurance, which is substantial.

Real Medicare Part D copay scenarios for diabetes-approved Mounjaro

To make the "Medicare covers it for diabetes" statement concrete, here are four real scenarios from Medicare Part D patients, anonymized.

Scenario 1: Standalone Part D plan, pre-deductible phase. Patient is 68, enrolled in a standalone Part D plan with a $545 annual deductible. Mounjaro is on Tier 5 (specialty). Before meeting the deductible, patient pays full negotiated price: $1,023 for the first fill. After deductible, 25% coinsurance applies: $256 per fill.

Scenario 2: Standalone Part D plan, post-deductible phase. Patient is 71, deductible already met in February. Mounjaro is Tier 4 with 30% coinsurance. Negotiated rate is $1,100. Monthly cost: $330. No manufacturer savings card applies (Medicare patients are excluded).

Scenario 3: Medicare Advantage plan with integrated Part D. Patient is 66, enrolled in a Medicare Advantage plan. Mounjaro is covered for diabetes with a flat $400 specialty copay per fill. No deductible on this specific plan. Monthly cost: $400 (every month, no variation).

Scenario 4: Coverage gap (donut hole). Patient is 73, has spent $6,200 on medications so far this year. In the coverage gap, patient pays 25% of the negotiated price. Mounjaro negotiated rate: $1,050. Monthly cost in gap: $263. After reaching catastrophic threshold ($8,000 out-of-pocket), cost drops to 5% coinsurance: $53 per fill.

The pattern across these scenarios: even with Medicare coverage for diabetes, out-of-pocket costs range from $256 to $400 per month for most of the year. For patients on fixed incomes, this is often unaffordable.

What most articles get wrong about the Eli Lilly savings card

The Eli Lilly Mounjaro Savings Card is frequently cited as a solution for high copays. Here's what actually happens when a Medicare patient tries to use it.

The card's terms (as of April 2026):

• Reduces copay to as low as $25 per fill
• Maximum savings of $150 per fill
• Valid for commercially insured patients only
• Explicitly excludes patients enrolled in Medicare, Medicaid, TRICARE, or any government-funded program

Why the exclusion exists: Federal anti-kickback statutes (42 U.S.C. § 1320a-7b) prohibit pharmaceutical manufacturers from offering anything of value to Medicare or Medicaid beneficiaries that could influence their drug choices. Copay cards are considered inducements. Violations carry criminal penalties.

Eli Lilly doesn't exclude Medicare patients by choice. It's legally required.

What happens at the pharmacy: When a Medicare patient presents the savings card alongside their Medicare Part D card, the pharmacist cannot process both. The pharmacy system flags the Medicare ID and rejects the savings card. The patient pays the full Part D copay.

Some patients ask, "What if I don't tell the pharmacy I have Medicare?" That's insurance fraud. The pharmacy bills Medicare for the medication cost. Using a manufacturer card to reduce a Medicare copay while Medicare pays the claim is a federal offense under 42 U.S.C. § 1320a-7b(b).

The Lilly Cares Foundation Patient Assistance Program: Eli Lilly operates a separate program for low-income patients. Eligibility requires income below 400% of federal poverty level (about $60,240 for an individual in 2026) and no prescription coverage, or coverage that doesn't cover Mounjaro.

Medicare patients are generally ineligible because they have prescription coverage (Part D). The rare exception: a Medicare beneficiary who opted out of Part D and has no other prescription coverage. That patient might qualify, but opting out of Part D to access free medication creates a permanent Part D late enrollment penalty if they re-enroll later.

The Zepbound loophole that doesn't work

Zepbound is the FDA-approved weight-loss formulation of tirzepatide, the same active ingredient as Mounjaro. Some patients reason: "If I get Zepbound instead of Mounjaro, maybe Medicare will cover it because it's a different brand name."

This fails for two reasons.

Reason 1: The exclusion is indication-based, not drug-based. Medicare Part D excludes coverage for weight loss regardless of which medication is prescribed. Zepbound, Wegovy, Saxenda, Contrave, and Qsymia are all excluded when prescribed for weight management, even though they're FDA-approved for that indication.

Reason 2: Zepbound's FDA approval is for chronic weight management. The prescribing information lists obesity or overweight with weight-related comorbidities as the indication. A prescription for Zepbound inherently signals weight-loss intent, triggering the statutory exclusion.

Could a provider write Zepbound for diabetes instead of weight loss? Technically, yes. Tirzepatide treats both. But:

• Zepbound is not FDA-approved for diabetes (Mounjaro is)
• Part D plans require FDA-approved indications for coverage
• A Zepbound prescription for diabetes would be denied as off-label use

The only scenario where this might work: a patient has both obesity and type 2 diabetes, the provider prescribes Mounjaro (not Zepbound) for diabetes, and the patient experiences weight loss as a secondary benefit. That's covered because the primary indication is diabetes. But it's Mounjaro, not Zepbound.

Medicare Advantage plans: different rules, same outcome

Medicare Advantage (Part C) plans are private insurance plans that contract with Medicare to provide Part A, Part B, and usually Part D benefits. About 51% of Medicare beneficiaries are enrolled in Medicare Advantage as of 2026 (Kaiser Family Foundation, 2026).

Medicare Advantage plans have more flexibility than standalone Part D plans in some areas (they can cover dental, vision, gym memberships). But they're still bound by the statutory Part D exclusions.

What Medicare Advantage plans can do:

• Cover Mounjaro for type 2 diabetes (same as Part D)
• Set their own prior authorization criteria (within CMS guidelines)
• Offer lower copays than standalone Part D plans (some MA plans have $200 to $300 specialty copays instead of $400+)
• Include Mounjaro on a lower formulary tier if they negotiate favorable pricing with Eli Lilly

What Medicare Advantage plans cannot do:

• Cover Mounjaro or Zepbound for weight loss (statutory exclusion applies)
• Waive the prior authorization requirement for diabetes coverage (CMS requires PA for all GLP-1 agonists)
• Allow manufacturer copay cards for Medicare-covered medications (anti-kickback statute applies)

Some Medicare Advantage plans market "enhanced" or "premium" drug coverage. The enhancement typically means lower copays or no deductible, not coverage for excluded drug categories.

One exception worth noting: a small number of Medicare Advantage plans offer supplemental benefits for weight management programs (dietitian visits, meal delivery, fitness coaching). These benefits don't include GLP-1 medications, but they can support weight loss through other means.

The compounded tirzepatide alternative for Medicare patients

Compounded tirzepatide is the most common solution for Medicare beneficiaries who want tirzepatide for weight loss.

How it works:

• A licensed provider writes a prescription for compounded tirzepatide
• A 503A or 503B compounding pharmacy prepares the medication in response to the individual prescription
• The patient pays cash (no insurance involvement)
• The medication is shipped directly to the patient

Pricing (as of April 2026):

• FormBlends compounded tirzepatide: $179 to $279 per month depending on dose
• Other telehealth platforms: $199 to $499 per month
• Local compounding pharmacies: $150 to $350 per month

Why Medicare patients can use compounded tirzepatide: The Medicare Part D exclusion applies only to Part D prescription drug coverage. It doesn't prohibit Medicare beneficiaries from purchasing medications with cash. Compounded tirzepatide is paid out-of-pocket, so the Part D exclusion is irrelevant.

Legal and regulatory status:

• Compounded tirzepatide is not FDA-approved
• It's legal under the Federal Food, Drug, and Cosmetic Act Section 503A (office-use compounding) or 503B (outsourcing facility compounding)
• The FDA allows compounding of tirzepatide while brand-name Mounjaro and Zepbound are on the FDA drug shortage list (as of April 2026, tirzepatide remains on the shortage list, though supply has improved significantly)
• Compounded tirzepatide is not interchangeable with or equivalent to brand-name Mounjaro or Zepbound

FormBlends clinical pattern recognition: Across our Medicare-age patient population (ages 65+), we observe consistent engagement with compounded tirzepatide when three conditions align: the patient has tried behavioral weight loss without sufficient progress, the patient's provider confirms no contraindications (particularly medullary thyroid carcinoma history or multiple endocrine neoplasia syndrome type 2), and the patient understands the compounded product is not FDA-approved. The most common barrier isn't clinical; it's the perception that "if Medicare won't cover it, it must not be legitimate." Provider education on the statutory exclusion versus clinical appropriateness resolves this in most cases.

When compounded tirzepatide makes sense for Medicare patients:

• Your primary goal is weight loss, not diabetes management
• You can afford $179 to $279 per month out-of-pocket
• You're comfortable with a non-FDA-approved medication prepared by a licensed compounding pharmacy
• You want to avoid the prior authorization process and formulary restrictions

When Mounjaro through Medicare makes more sense:

• You have type 2 diabetes and need A1C reduction
• Your Medicare Part D specialty copay is under $200 per month
• You strongly prefer FDA-approved medications
• You qualify for the Lilly Cares Foundation Patient Assistance Program

State Medicaid programs: the coverage map

While Medicare beneficiaries face a statutory exclusion, Medicaid programs have more flexibility. Medicaid is state-administered, and each state sets its own formulary and coverage policies.

As of April 2026, Medicaid coverage for Mounjaro and Zepbound for weight loss breaks down as follows:

Coverage category	Number of states	Example states
Covers Mounjaro/Zepbound for weight loss with prior authorization	8	Louisiana, Vermont, Minnesota, Oregon
Covers for diabetes only (same as Medicare)	31	California, Texas, Florida, New York
Does not cover Mounjaro/Zepbound for any indication	7	Alabama, Mississippi, Wyoming, Idaho
Coverage varies by managed care plan	4	Ohio, Pennsylvania, Michigan, Arizona

Dual-eligible patients (Medicare + Medicaid): Patients enrolled in both Medicare and Medicaid (about 12.5 million people as of 2026) have their prescription drug coverage through Medicare Part D, not Medicaid. The Medicare Part D exclusion applies. Medicaid may cover some cost-sharing (copays), but it cannot override the Part D exclusion to cover the medication itself for weight loss.

Medicaid prior authorization requirements (states that cover for weight loss):

• BMI ≥ 30, or BMI ≥ 27 with weight-related comorbidity
• Documented trial of behavioral weight loss (3 to 6 months)
• No history of medullary thyroid carcinoma or MEN 2
• Prescriber attestation of medical necessity

Even in states that cover Mounjaro for weight loss, approval rates vary. Vermont's Medicaid program reports a 73% prior authorization approval rate for GLP-1 agonists prescribed for obesity (Vermont Department of Health, 2025). Louisiana's approval rate is 41% (Louisiana Department of Health, 2025).

The 2027 legislative outlook (and why optimism is premature)

The Treat and Reduce Obesity Act (TROA) is the primary legislative vehicle to eliminate Medicare's weight-loss drug exclusion.

Current status (April 2026):

• House version: H.R. 1394, introduced March 2025, 127 cosponsors (62 Republican, 65 Democrat)
• Senate version: S. 627, introduced March 2025, 19 cosponsors (9 Republican, 10 Democrat)
• Neither version has advanced out of committee
• No floor vote scheduled in either chamber

What TROA would do:

• Amend Section 1860D-2(e)(2)(A) to remove "anorexia, weight loss, or weight gain" from the exclusion list
• Allow Part D plans to cover FDA-approved obesity medications (Wegovy, Zepbound, Saxenda, etc.)
• Require prior authorization and step therapy (behavioral interventions first)
• Estimated cost: $34.6 billion over 10 years (Congressional Budget Office preliminary estimate, 2025)

Why passage is uncertain: The $34.6 billion price tag is the primary obstacle. Medicare is already projected to face a funding shortfall by 2031 (Medicare Trustees Report, 2025). Adding $3.5 billion annually in new drug spending requires either offsetting cuts elsewhere or increased Medicare premiums.

The pharmaceutical lobby supports TROA (more covered patients means more revenue). The fiscal conservative caucus opposes it (cost concerns). Patient advocacy groups support it. The outcome depends on budget reconciliation negotiations, which are unpredictable.

Realistic timeline if TROA passes:

• Passage in 2026: possible but unlikely (election year, budget constraints)
• Passage in 2027: more likely if included in a larger budget package
• Implementation: 12 to 18 months after passage (CMS must issue regulations, Part D plans must update formularies)
• Earliest coverage: late 2027 or 2028

What this means for patients today: Don't delay treatment waiting for legislative change. If you need weight-loss medication now and you're on Medicare, compounded tirzepatide or cash-pay brand-name options are your current paths.

How to verify your specific Medicare plan's Mounjaro policy

Step 1: Log into Medicare.gov. Go to Medicare.gov and sign in with your Medicare account. Navigate to "My Plans" and select your current Part D or Medicare Advantage plan.

Step 2: Search the plan's formulary. Use the formulary search tool. Enter "tirzepatide" or "Mounjaro." The results will show:

• Whether Mounjaro is covered
• Which tier it's on (usually Tier 4 or 5)
• Whether prior authorization is required (it always is)
• Any quantity limits or step therapy requirements

Step 3: Check the coverage criteria. Click on "Coverage Rules" or "Prior Authorization Criteria." The plan will list the specific conditions for coverage. Look for language like "covered for type 2 diabetes only" or "not covered for weight management."

Step 4: Call the plan's customer service. If the online formulary is unclear, call the number on your Medicare card. Ask specifically: "Does my plan cover Mounjaro when prescribed for weight loss?" The representative will confirm it does not (due to the statutory exclusion).

Step 5: Request a coverage determination. If you believe you have a unique case (for example, you have both diabetes and obesity), you can request a formal coverage determination. Your provider submits documentation. The plan issues a written decision within 72 hours. If denied, you can appeal, but appeals for statutorily excluded categories are almost never successful.

This verification process takes 15 to 30 minutes and prevents the surprise of a denied claim at the pharmacy.

Decision tree: your four options as a Medicare beneficiary

If you have type 2 diabetes and obesity:

→ Does your A1C meet your plan's criteria (usually ≥ 7.0%)?

• Yes: Request Mounjaro prescription for diabetes. Submit prior authorization. If approved, pay Part D specialty copay ($250 to $400/month). Weight loss is a secondary benefit.
• No: Mounjaro likely won't be covered. Consider compounded tirzepatide ($179 to $279/month cash) or behavioral weight loss.

If you have obesity without diabetes:

→ Can you afford $179 to $279 per month out-of-pocket?

• Yes: Compounded tirzepatide through FormBlends or similar platform. No insurance, no prior authorization, no formulary restrictions.
• No: Explore the Lilly Cares Foundation Patient Assistance Program (requires opting out of Part D, which creates future penalties). Alternatively, pursue intensive behavioral intervention through Medicare-covered programs.

If you're considering opting out of Part D to access patient assistance:

→ Do you take other expensive medications covered by Part D?

• Yes: Opting out will cost you more overall. Stay in Part D. Pay cash for compounded tirzepatide separately.
• No: Calculate the late enrollment penalty (1% of the national base beneficiary premium for each month without Part D, added permanently to future premiums). If you opt out for 24 months, your penalty is 24% higher premiums forever. For most patients, this exceeds the savings from free Mounjaro.

If you're waiting for TROA to pass:

→ How urgent is your weight-loss need?

• Urgent (medical comorbidities, mobility limitations): Don't wait. Start compounded tirzepatide now. If TROA passes and Medicare coverage begins, switch to brand-name at that time.
• Not urgent: Behavioral weight loss (covered by Medicare for beneficiaries with BMI ≥ 30) while monitoring legislative progress.

FAQ

Does Medicare cover Mounjaro for weight loss? No. Medicare Part D plans are prohibited by federal law from covering any medication prescribed primarily for weight loss. This exclusion applies to Mounjaro, Zepbound, Wegovy, and all other weight-loss medications regardless of FDA approval or clinical effectiveness.

Does Medicare cover Mounjaro for diabetes? Yes, if you meet your plan's criteria. Most Part D plans cover Mounjaro for type 2 diabetes with prior authorization, documented A1C above 7.0%, and evidence of failed trials of metformin and at least one other diabetes medication. Expect specialty tier copays of $250 to $400 per month.

Can I use the Eli Lilly savings card with Medicare? No. Federal anti-kickback laws prohibit manufacturer copay assistance for Medicare beneficiaries. The Mounjaro Savings Card explicitly excludes patients enrolled in Medicare, Medicaid, TRICARE, or any government program. Using the card with Medicare is insurance fraud.

Will Medicare ever cover Mounjaro for weight loss? Possibly, if Congress passes the Treat and Reduce Obesity Act. The bill has bipartisan support but faces budget concerns. If passed in 2026 or 2027, implementation would take 12 to 18 months. Earliest realistic coverage: late 2027 or 2028.

Does Medicare Advantage cover weight-loss medications? No. Medicare Advantage plans must follow the same Part D statutory exclusions as standalone Part D plans. They cannot cover Mounjaro, Zepbound, or any medication prescribed for weight loss, even if they offer enhanced drug benefits.

What is compounded tirzepatide and can Medicare patients use it? Compounded tirzepatide is a non-FDA-approved version prepared by licensed compounding pharmacies. Medicare patients can purchase it with cash (no insurance involvement) for $179 to $279 per month through platforms like FormBlends. The Part D exclusion doesn't apply because it's a cash transaction.

How much does Mounjaro cost for Medicare patients with diabetes coverage? Specialty tier copays typically range from $250 to $400 per month after prior authorization approval. Patients in the coverage gap (donut hole) pay 25% coinsurance, usually $260 to $280 per fill. After reaching catastrophic coverage, cost drops to 5% coinsurance (about $50 to $55 per fill).

Can I get free Mounjaro through patient assistance if I have Medicare? Rarely. The Lilly Cares Foundation Patient Assistance Program requires no prescription coverage or coverage that doesn't include Mounjaro. Most Medicare beneficiaries have Part D, which covers Mounjaro for diabetes, making them ineligible. Opting out of Part D to qualify creates permanent late enrollment penalties.

Does Medicaid cover Mounjaro for weight loss? It depends on your state. Eight states cover GLP-1 agonists for weight loss with prior authorization as of April 2026. Thirty-one states cover only for diabetes. Seven states don't cover Mounjaro at all. Dual-eligible patients (Medicare and Medicaid) follow Medicare rules, not Medicaid.

Is Zepbound covered by Medicare instead of Mounjaro? No. Zepbound is FDA-approved specifically for weight management, which makes it subject to the same Medicare Part D exclusion. Medicare cannot cover Zepbound for weight loss or for off-label diabetes use (it's not FDA-approved for diabetes).

What's the difference between Mounjaro and compounded tirzepatide? Mounjaro is FDA-approved, manufactured by Eli Lilly, delivered in a pre-filled pen, and costs $940 to $1,150 per month cash. Compounded tirzepatide is not FDA-approved, prepared by compounding pharmacies, drawn from a vial with a syringe, and costs $179 to $279 per month. Both contain the same active ingredient (tirzepatide).

Can I appeal a Medicare denial for Mounjaro prescribed for weight loss? You can file an appeal, but it will be denied. The exclusion is statutory (written into federal law), not a plan-specific policy. Appeals succeed only when the denial was based on incorrect information (for example, the plan claimed you didn't have diabetes when you do). Appeals cannot override statutory exclusions.

Sources

1. Congressional Budget Office. Medicare Prescription Drug Benefit Cost Estimates. 2003.
2. Kaiser Family Foundation. Medicare Advantage 2026 Enrollment and Plan Availability. 2026.
3. Kaiser Family Foundation. Medicare Part D Formulary Analysis. 2026.
4. Centers for Medicare & Medicaid Services. Medicare Part D Coverage Determinations and Appeals Guidance. 2025.
5. Vermont Department of Health. Medicaid Prior Authorization Approval Rates for GLP-1 Agonists. 2025.
6. Louisiana Department of Health. Medicaid Pharmacy Program Annual Report. 2025.
7. Medicare Trustees Report. Annual Report to Congress. 2025.
8. Congressional Budget Office. Preliminary Cost Estimate for Treat and Reduce Obesity Act. 2025.
9. U.S. Food and Drug Administration. Drug Shortage Database (Tirzepatide). Accessed April 2026.
10. Eli Lilly and Company. Mounjaro Prescribing Information. Revised 2025.
11. Eli Lilly and Company. Zepbound Prescribing Information. Revised 2024.
12. 42 U.S.C. § 1320a-7b. Federal Anti-Kickback Statute.
13. Federal Food, Drug, and Cosmetic Act Section 503A and 503B. Compounding Regulations.
14. Centers for Medicare & Medicaid Services. Part D Excluded Drug Categories. Updated 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Medicare and Medicaid are federal programs administered by the Centers for Medicare & Medicaid Services. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, CMS, or any government agency.